Evaluating the inter and intra batch variability of protein aggregation behaviour using Taylor dispersion analysis and dynamic light scattering

International Journal of Pharmaceutics

Volumn 453, Issue 2, 2013, Pages 351-357

  Hulse, Wendy L ^a   Gray, Jason ^a   Forbes, Robert T ^b  

^a Allembis Ltd   (United Kingdom)

^b UNIVERSITY OF BRADFORD   (United Kingdom)

Author keywords

Aggregation; Biosimilar; Dynamic light scattering; Hydrodynamic radius; Taylor dispersion analysis

Indexed keywords

A 2058; A 2153; A 8654; BOVINE SERUM ALBUMIN; EXCIPIENT; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ARTICLE; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; DISPERSION; HEAT SHOCK; HYDRODYNAMICS; IMMUNOGENICITY; LIGHT SCATTERING; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN STRUCTURE; TAYLOR DISPERSION ANALYSIS;

EID: 84884147610     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2013.05.062     Document Type: Article

References (32)

1. CFR320, 2004. Code of Federal Regulations. Title 21, Volume 5. U.S. Food and Drug Administration (FDA).
2. Aschi, A., Mbarek, N., Othman, M., Gharbi, A., 2008. Study of thermally and chemically unfolded conformations of bovine serum albumin by means of dynamic light scattering. Mater. Sci. Eng. C 28, 594-600.
3. Barbosa, D.F.S., 2011. Immunogenicity of biotherapeutics in the context of developing biosimilars and biobetters. Drug Discov. Today 16 (7/8), 345-353.
4. Brahma, A., Mandal, C., Bhattacharyya, D., 2005a. Characterisation of a dimeric unfolding intermediate of bovine serum albumin under mildly acidic condition. Biochim. Biophys. Acta 1751, 159-169. (Pubitemid 41112234)
5. Baumann, A., 2009. Nonclinical development of biopharmaceuticals. Drug Discov. Today 14, 1112-1122.
6. Brahma, A., Mandal, C., Bhattacharyya, D., 2005b. Characterisation of a dimeric unfolding intermediate of bovine serum albumin under mildly acidic conditions. Biochim. Biophys. Acta 1751, 159-169. (Pubitemid 41112234)
7. Buttel, I.C., Chamberlain, P., Chowers, Y., Ehmann, F., Greinacher, A., Jeffries, R., Kramer, D., Kropshofer, H., Lloyd, P., Lubiniecki, A., Krause, R., Mire-Sluis, A., Platts-Mills, T., Ragheb, J.A., Reipert, B.M., Schellekens, H., Seitz, R., Stas, P., ubramanyam, M., Thorpe, R., Trouvin, J.-H., Weise, M., Windish, J., Schneider, C.K., 2011. Taking immunogenicity assessment of therapeutic proteins to the next level. Biologicals 39, 100-109.
8. Combe, C., Tredree, R.L., Schellekens, H., 2005. Biosimilar epo etins: an analysis based on recently implemented European medicines evaluation agency guidelines on comparability of biopharmaceutical proteins. Pharmacotherapy 25 (7), 954-962. (Pubitemid 40917928)
9. Cromwell, M.E., Hilario, E., Jacobson, F., 2006. Protein aggregation and bioprocessing. AAPS J. 8 (3), 572-579.
10. FDA, 2012. Guidance for Industry Scientific Considerations in Demonstrating Biosimilarity to a Reference Product.
11. Hawe, A., Hulse, W.L., Jiskoot, W., Forbes, R.T., 2011. Taylor dispersion analysis compared to dynamic light scattering for the size analysis of therapeutic peptides and proteins and their aggregates. Pharm. Res. 28 (9), 2302-2310.
12. Hulse, W.L., Forbes, R.T., 2011a. A nanolitre method to determine the hydrodynamic radius of proteins and small molecules by Taylor dispersion analysis. Int. J. Pharm. 411, 64-68.
13. Hulse, W.L., Forbes, R.T., 2011b. A Taylor dispersion analysis method for the sizing of therapeutic proteins and their aggregates using nanolitre sample quantities. Int. J. Pharm. 416, 394-397.
14. Jeske, W., Litinas, E., Khan, H., Happensteaddt, D., Fareed, J., 2012. A comparison of the pharmacodynamic behavior of branded and biosimilar enoxaparin in primates. Clin. Appl. Thromb Hemost. 18 (3), 294-298.
15. Kane, M.T., 1983. Variability in different lots of commercial bovine serum albumin affects cell multiplication and hatching of rabbit blastocysts in culture. J. Reprod. Fert. 69, 555-558. (Pubitemid 13021959)
16. Kessler, M., Goldsmith, D., Schelllekens, H., 2006. Immunogenicity of biopharmaceuticals. Nephrol. Dial. Transplant. 21 (Suppl. 5), V9-V12. (Pubitemid 44391026)
17. Kresse, G.-B., 2009. Biosimilars-science, status and strategic perspective. Eur. J. Pharm. Biopharm. 72, 479-486.
18. Longstaff, C., Whitton, C.M., Stebbings, R., Gray, E., 2009. How do we assure the quality of biological medicines? Drug Discov. Today 14 (1/2), 50-55.
19. Lumry, R., Eyring, H., 1953. Conformation changes of proteins. J. Phys. Chem. 58, 110-120.
20. Maruyama, T., Katoh, S., Nakajima, M., Nabetani, H., 2001. Mechanism of bovine serum albumin aggregation during ultrafiltration. Biotech. Bioeng. 75 (2), 233-238. (Pubitemid 32937295)
21. Militello, V., Casarno, C., Emanuele, A., Giostra, A., Pullara, F., Pullara, F., Leone, M., 2004. Aggregation kinetics of bovine serum albumin studied by FTIR spectroscopy and light scattering. Biophys. Chem. 107, 175-187. (Pubitemid 38220958)
22. Minghetti, P., Rocco, P., Cilurzo, P., Del Vecchio, L., Locatelli, F., 2012. The regulatory framework of biosimilars in the European union. Drug Discov. Today 17 (1-2), 63-70.
23. Minton, K.W., Karmin, G.M., Hahn Minton, A.P., 1982. Nonspecific stabilisation of stress-susceptible proteins by stress resistant proteins; a model for the biological role of heat shock proteins. Biochemistry 79, 7107-7111.
24. Patten, P.A., Schellekens, H., 2003. The immunogenicity of biopharmaceuticals. Lessons learned and consequences for protein drug development. Dev. Biol. (Basel) 112, 81-97.
25. Raw, A.S., Furness, M.S., Gill, D.S., Adams, R.C., Holcombe Jr., F.O., Yu, L.X., 2004. Regulatory considerations of pharmaceutical solid polymorphism in Abbreviated New Drug Applications (ANDAs). Adv. Drug Deliv. Rev. 56, 391-414.
26. Ruiz-Pena, M., Oropesa-Nunez, R., Pons, T., Louro, S.R.W., Perez-Gramatges, A., 2010. Physico-chemical studies of molecular interactions between non-ionic surfactants and bovine serum albumin. Colloids Surf. B: Biointerfaces 75, 282-289.
27. Schellekens, H., 2009. Assesing the bioequivalence of biosimilars. Drug Discov. Today 14 (9/10), 495-499.
28. Schellekens, H., Klinger, E., Muhlebach, S., Brin, J.-F., Storm, G., Crommelin, D.J.A., 2011. The therapeutic equivalence of complex drugs. Regul. Toxicol. Pharmacol. 59, 176-183.
29. Sharma, A., Agarwal, P.K., Deep, S., 2010. Characterisation of different conformations of bovine serum albumin and their propensity to aggregate in the presence of N-cetyl-N,N,N-trimethyl ammonium bromide. J. Coll. Int. Sci. 343, 454-462.
30. Weise, M., Bielsky, M-C., Smet, K.D., Ehmann, F., Ekman, N., Gopalan, N., Heim, H-K., Heinonen, E., Ho, K., Thorpe, R., Vleminckx, C., Wadhwa, M., Schneider, C., 2011. Biosimilars - why terminology matters? Nat. Biotechnol. 29, 690-693.
31. Yu, L.X., Furness, M.S., Raw, A., Woodland Outlaw, K.P., Nashed, N.E., Ramos, E., Miller, S.P.F., Adams, R.C., Fang, F., Patel, R.M., Holcombe F.O. Jr., Chiu, Y., Hussain, A.S., 2003. Scientific considerations of pharmaceutical solid polymorphism in abbreviated new drug applications. Pharm. Res. 20 (4), 531-536. (Pubitemid 36438894)
32. Zuniga, L., Calvo, B., 2010. Biosimilars approval process. Regul. Toxicol. Pharmacol. 56 (3), 374-377.